Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.34 EUR
Change Today +0.126 / 2.42%
Volume 0.0
TG4 On Other Exchanges
Symbol
Exchange
EN Brussels
OTC US
Berlin
As of 10:10 AM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

thrombogenics nv (TG4) Snapshot

Open
€5.24
Previous Close
€5.21
Day High
€5.34
Day Low
€5.19
52 Week High
07/29/14 - €9.54
52 Week Low
04/2/15 - €4.69
Market Cap
192.6M
Average Volume 10 Days
100.0
EPS TTM
--
Shares Outstanding
36.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THROMBOGENICS NV (TG4)

Related News

No related news articles were found.

thrombogenics nv (TG4) Related Businessweek News

No Related Businessweek News Found

thrombogenics nv (TG4) Details

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes ophthalmic and oncology medicines in Belgium and internationally. The company’s lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat various disorders, such as cancer, age-related macular degeneration, retinopathy, and inflammation; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc. to provide clinical research services for the development of JETREA. The company was founded in 1991 and is headquartered in Leuven, Belgium.

120 Employees
Last Reported Date: 04/4/15
Founded in 1991

thrombogenics nv (TG4) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €690.0K
Executive Director
Total Annual Compensation: --
Executive Director and Member of Audit Commit...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

thrombogenics nv (TG4) Key Developments

ThromboGenics Announces Appointment of Emmanuele Attout as Independent Non-Executive Director

In January, ThromboGenics nominated Emmanuele Attout to be its new Independent non-executive director. Mrs. Attout was appointed during the ThromboGenics Annual Shareholders Meeting of May 5, 2015. She will also join the Audit Committee of the Company. Mrs. Attout has been an audit partner at PricewaterhouseCoopers since 1994. She has been in charge of the audits for a wide range of clients, including in recent years being in charge of the audits of publicly listed pharmaceutical companies and life sciences businesses.

ThromboGenics Reports Positive Top-Line Results from the OASIS Study

ThromboGenics reported positive top-line results from the OASIS study. This randomized controlled study met its primary endpoint with 41.7% of patients treated with JETREA(R) achieving VMA resolution at day 28 post injection compared with only 6.2% of patients who received a sham injection (p<0.001). This was a positive result which is in line with the JETREA(R) real-world experiences of the retina community and more favourable than the results of the pivotal Phase III program where VMA resolution was seen in only 26.5% of patients. The study also showed that the JETREA(R) safety profile in this 24 month follow-up study was consistent with the drug's overall safety profile as known from the approved label. ThromboGenics, and its partner Alcon, presented a number of new data posters on JETREA(R) at the ARVO (The Association for Research in Vision and Ophthalmology) meeting in Denver May 3-7. The majority of these posters showed additional positive real world data on JETREA(R), which provided further important insights into the value that this novel medicine provides, reinforcing the findings of the OASIS study. ThromboGenics' sales team is focused on key accounts. These accounts comprise retina specialists who have already achieved experience and satisfactory clinical or real-world results with JETREA(R). This approach is designed to allow ThromboGenics to capitalize on the real-world data that has and will continue to emerge during the course of 2015 to drive the adoption of JETREA(R). ThromboGenics is on track to recruit the first patient in its Phase IIa clinical study assessing JETREA(R) for the treatment of diabetic retinopathy (DR) before the end of 2015. DR is the second indication that ThromboGenics is developing JETREA(R). ThromboGenics has also announced the start of the evaluation and development of JETREA(R) for the treatment of Retinal Vein Occlusion (RVO). RVO is the third indication the Company will develop JETREA(R) for. The company has received an IWT grant to conduct pre-clinical research related to this indication. RVO is known to be the second most common retinal vascular disease, and thought to negatively impact the quality of life of 16 million patients worldwide.

ThromboGenics NV Presents at CF&B European Small Cap Event, Apr-27-2015

ThromboGenics NV Presents at CF&B European Small Cap Event, Apr-27-2015 . Venue: Paris, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TG4:GR €5.34 EUR +0.126

TG4 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TG4.
View Industry Companies
 

Industry Analysis

TG4

Industry Average

Valuation TG4 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.6x
Price/Book 0.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THROMBOGENICS NV, please visit www.thrombogenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.